Sequenom Preliminary Full-year 2012 Revenues Grow 59 Percent to $89M | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom on Sunday said that it expects its full-year 2012 revenues to grow 59 percent year-over-year to $89 million.

Based on the company's preliminary financial results, diagnostic services grew more than five-fold during the year to about $46 million, compared to $8.3 million in 2011, while Genetic Analysis posted $43 million in sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.